CRISPR IN DRUG DISCOVERY 2022: FROM TARGETS TO THERAPEUTICS
The fourth CRISPR in Drug Discovery: From Targets to Therapeutics meeting will be held face to face in Cambridge, March 1-2, 2022.
Genome engineering especially CRISPR/Cas9, has become a powerful tool throughout the drug discovery pipeline. This meeting will focus on the application of genome engineering in identification of novel drug targets through large scale CRISPR based functional genomics studies, developing advanced cellular and in vivo disease models for target validation, and its pioneering applications in therapeutic genome editing.
The meeting will focus on providing a current perspective of the applications of these rapidly developing technologies with an emphasis on drug discovery applications. The scientific program for this meeting will include:
- Large-scale CRISPR functional genomics studies for drug target identification and validation
- Application of genome engineering in developing biological models of disease from single cells through to complex in vitro tissue systems and in vivo models
-Cutting edge CRISPR genome engineering technologies and their emerging applications
- A perspective from technology leaders on the therapeutic applications of genome engineering
We aim to bring together the research community working in the field of genome engineering with interests in developing and applying the technology for pharmaceutical research.
Join scientists from academia, pharma, biotech, and CRO’s to hear talks given by speakers at the cutting edge of genome engineering, network at the exhibition, and gain strategic insights into solutions for increasing the success of drug discovery and development.
Andrew Bassett (Wellcome Sanger Institute),
Klio Maratou (GlaxoSmithKline)
Marcello Maresca (AstraZeneca)
Venue: Babraham Research Campus
Location: The Cambridge Building, Babraham Research Campus, Cambridge
Country: United Kingdom
Organiser Contact Details:
T: 07484 email@example.com